Literature DB >> 9700638

Estimated susceptibility to asymptomatic secondary immune response against measles in late convalescent and vaccinated persons.

B Damien1, S Huiss, F Schneider, C P Muller.   

Abstract

Serological evidence indicates that measles virus (MV) could circulate in seropositive, fully protected populations. Among individuals fully protected against disease, those prone to asymptomatic secondary immune response are the most likely to support subclinical MV transmission. The serological characteristics of protected subjects who developed secondary immune response after reexposure to measles have been described recently [Huiss et al. (1997): Clinical and Experimental Immunology 109:416-420]. On the basis of these data, a threshold of susceptibility was defined to estimate frequencies of secondary immune response competence in different populations. Among measles, late convalescent adults (n = 277) and vaccinated high school children (n = 368), 3.2-3.9% and 22.2-33.2%, respectively, were considered susceptible to secondary immune response. A second vaccination did not seem to lower this incidence. Even when estimates of symptomatic secondary immune response (e.g., secondary vaccine failure) were taken into account, susceptibility to subclinical secondary immune response was still 5-8 times higher after vaccination than after natural infection. Although viral transmission between protected individuals has never been directly demonstrated, the data describe a population in which protected but infectious persons could potentially be of epidemiological importance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700638     DOI: 10.1002/(sici)1096-9071(199809)56:1<85::aid-jmv14>3.0.co;2-v

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Recombinant measles viruses efficiently entering cells through targeted receptors.

Authors:  U Schneider; F Bullough; S Vongpunsawad; S J Russell; R Cattaneo
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Evaluation of commercial assay detecting specific immunoglobulin g in oral fluid for determining measles immunity in vaccinees.

Authors:  Jacques R Kremer; Claude P Muller
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

3.  Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups.

Authors:  Masae Itoh; Yoshinobu Okuno; Hak Hotta
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

4.  Performance Evaluation of the VIDAS(®) Measles IgG Assay and Its Diagnostic Value for Measuring IgG Antibody Avidity in Measles Virus Infection.

Authors:  Julia Dina; Christian Creveuil; Stephanie Gouarin; Florent Viron; Amelie Hebert; Francois Freymuth; Astrid Vabret
Journal:  Viruses       Date:  2016-08-20       Impact factor: 5.048

5.  Measles resurgence in Brazil: analysis of the 2019 epidemic in the state of São Paulo.

Authors:  Cristina Makarenko; Alexandre San Pedro; Natalia Santana Paiva; Jefferson Pereira Caldas Dos Santos; Roberto de Andrade Medronho; Gerusa Gibson
Journal:  Rev Saude Publica       Date:  2022-06-13       Impact factor: 2.772

6.  Estimating the nationwide transmission risk of measles in US schools and impacts of vaccination and supplemental infection control strategies.

Authors:  Parham Azimi; Zahra Keshavarz; Jose Guillermo Cedeno Laurent; Joseph G Allen
Journal:  BMC Infect Dis       Date:  2020-07-11       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.